Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
This study will also ask if patients with uncontrolled type 2 diabetes currently managed on diabetes pills + once daily insulin will choose as the next treatment choice to take insulin multiple times a day if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Educational Materials | Procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Will availability of inhaled insulin result in more type 2 diabetes patients choosing a treatment that involves insulin (if now on >2 OAs) or a more intensive insulin regimen (if now on OAs + glargine) compared to only standard therapies available |
| Measure | Description | Time Frame |
|---|---|---|
| Determine both patient and MD reasons for treatment choices made. Determine if treatment choice is influenced by physician specialty or patient ethnicity. Determine how cost impacts patient treatment choice. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Chandler | Arizona | 85224 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mesa |
| Arizona |
| 85201 |
| United States |
| Pfizer Investigational Site | Phoenix | Arizona | 85006-2850 | United States |
| Pfizer Investigational Site | Phoenix | Arizona | 85051 | United States |
| Pfizer Investigational Site | Tempe | Arizona | 85282 | United States |
| Pfizer Investigational Site | Los Angeles | California | 90033 | United States |
| Pfizer Investigational Site | San Diego | California | 92120 | United States |
| Pfizer Investigational Site | Colorado Springs | Colorado | 80904 | United States |
| Pfizer Investigational Site | Newark | Delaware | 19713 | United States |
| Pfizer Investigational Site | Wilmington | Delaware | 19805 | United States |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010-2934 | United States |
| Pfizer Investigational Site | Jacksonville | Florida | 32205 | United States |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | United States |
| Pfizer Investigational Site | Hayden | Idaho | 83835 | United States |
| Pfizer Investigational Site | Nampa | Idaho | 83714 | United States |
| Pfizer Investigational Site | Gurnee | Illinois | 60031 | United States |
| Pfizer Investigational Site | Elkton | Maryland | 21921 | United States |
| Pfizer Investigational Site | Detroit | Michigan | 48235 | United States |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55416 | United States |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | United States |
| Pfizer Investigational Site | Omaha | Nebraska | 68131 | United States |
| Pfizer Investigational Site | Margate City | New Jersey | 08402-2218 | United States |
| Pfizer Investigational Site | Santa Fe | New Mexico | 87505 | United States |
| Pfizer Investigational Site | New York | New York | 10016 | United States |
| Pfizer Investigational Site | Morehead City | North Carolina | 28557 | United States |
| Pfizer Investigational Site | Salisbury | North Carolina | 28144 | United States |
| Pfizer Investigational Site | Statesville | North Carolina | 28625 | United States |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103 | United States |
| Pfizer Investigational Site | Cincinnati | Ohio | 45236 | United States |
| Pfizer Investigational Site | Portland | Oregon | 97219 | United States |
| Pfizer Investigational Site | Portland | Oregon | 97239 | United States |
| Pfizer Investigational Site | Orangeburg | South Carolina | 29118 | United States |
| Pfizer Investigational Site | Simpsonville | South Carolina | 29681 | United States |
| Pfizer Investigational Site | Arlington | Texas | 76014-2010 | United States |
| Pfizer Investigational Site | Dallas | Texas | 75231 | United States |
| Pfizer Investigational Site | Madisonville | Texas | 77864 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | United States |
| Pfizer Investigational Site | Bennington | Vermont | 05201-5018 | United States |
| Pfizer Investigational Site | Virginia Beach | Virginia | 23462 | United States |
| Pfizer Investigational Site | Spokane | Washington | 99207 | United States |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | United States |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53218 | United States |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided